Table 2.
Hazard Ratios of YKL‐40 When Used Alone and Adjusted for the Rest of the Standard Predictors in the Placebo Group of the CLARICOR Trial
| Outcome | YKL‐40 Used Alone | YKL‐40 Adjusted for Standard Predictors | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI of HR | P Values | HR | 95% CI of HR | P Values | |
| Unstable angina pectoris | 1.09 | 0.93 to 1.29 | 0.28 | 0.99 | 0.83 to 1.19 | 0.94 |
| Acute myocardial infarction | 1.36 | 1.18 to 1.56 | <0.0001 | 1.19 | 1.02 to 1.40 | 0.028 |
| Cerebrovascular disease | 1.18 | 0.99 to 1.40 | 0.06 | 0.95 | 0.78 to 1.16 | 0.64 |
| Cardiovascular death | 1.67 | 1.44 to 1.93 | <0.0001 | 1.23 | 1.03 to 1.47 | 0.025 |
| Composite outcome | 1.35 | 1.24 to 1.47 | <0.0001 | 1.13 | 1.03 to 1.24 | 0.013 |
| All‐cause mortality | 1.76 | 1.59 to 1.95 | <0.0001 | 1.32 | 1.17 to 1.49 | <0.0001 |
Composite outcome including acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, or all‐cause mortality. HR indicates hazard ratio; CLARICOR, Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease.